|
The following projects represent some of the work being conducted in our labs and in the research facilities of our collaborative partners. NON-VIRAL INFLUENZA VACCINE DEVELOPMENT Molecular Express is developing a VesiVax® vaccine for influenza that incorporates the highly conserved ectodomain of the structural M2 protein... More details... | GENITAL HERPES VACCINE DISCOVERY Molecular Express has recently demonstrated that HSV2 VesiVax® vaccines targeted to selected epitopes from the gD viral envelope... More details... | ASPERGILLUS VACCINE Using the VesiVax® system, Molecular Express is constructing several vaccine candidates for testing in relevant animal models... More details... | LIPOSOMAL ADJUVANT FOR VACCINE Molecular Express has been developing a new model of immunization that is based on a flexible antigen delivery platform technology designed to... More details... | | LIPOSOMAL HIV VACCINE DEVELOPMENT Using the VesiVax® platform technology, Molecular Express plans to develop a vaccine against HIV based on the relatively conserved... More details... |
|
